SCHEMBL3470529

SCHEMBL3470529

OC1(C2CC2)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7464551 0.86
SCHEMBL238215 0.86
SCHEMBL18502945 0.85 OPRM1 (0.33)
SCHEMBL18563324 0.85 OPRM1 (0.33)
SCHEMBL19245878 0.85 OPRM1 (0.33)
SCHEMBL18566703 0.83 OPRM1 (0.44)
SCHEMBL8602855 0.83 MET (0.36)
SCHEMBL12764019 0.80
SCHEMBL1249492 0.79
SCHEMBL17207678 0.79 CHRNB2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118388307-A Method for synthesizing bicyclopropenyl high-energy fuel with high selectivity 龙子湖新能源实验室 2024-07-26 CN claimed
US-20260092047-A1 MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR VERTEX PHARMA (US) 2026-04-02 US disclosed
US-12384762-B2 Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-08-12 US disclosed
US-20240368189-A1 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators VERTEX PHARMA (US) 2024-11-07 US disclosed
US-12122788-B2 Process of making CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-22 US disclosed
US-20240277795-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF PARDES BIOSCIENCES INC (US) 2024-08-22 US disclosed
EP-4387980-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-06-26 EP disclosed
EP-4013741-B1 PROCESS OF MAKING CFTR MODULATORS VERTEX PHARMA (US) 2024-04-17 EP disclosed
CN-117843619-A Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and methods for preparing the modulators 弗特克斯药品有限公司 2024-04-09 CN disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 US disclosed
EP-1660477-B1 NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS SCHERING CORP (US) 2008-12-10 EP disclosed
EP-1660477-B1 NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS SCHERING CORP (US) 2008-12-10 EP disclosed
WO-2008137779-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-11-13 WO disclosed
WO-2008137779-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-11-13 WO disclosed
EP-1660477-A1 NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS Schering Corporation (US) 2006-05-31 EP disclosed
WO-2005014577-A9 NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS SCHERING CORP (US) 2006-03-23 WO disclosed
EP-1615898-A1 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE Novartis AG (CH) 2006-01-18 EP disclosed
US-20050059672-A1 Novel farnesyl protein transferase inhibitors as antitumor agents SCHERING CORPORATION 2005-03-17 US disclosed
WO-2005014577-A1 NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS SCHERING CORPORATION (US) 2005-02-17 WO disclosed
WO-2004089913-A1 AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE NOVARTIS AG (CH) 2004-10-21 WO disclosed